NCT07487441Not yet recruiting
Reverse Remodeling of the Pulmonary Vasculature: a Longitudinal, Investigational Study of the Effects of Sotatercept.
Source: ClinicalTrials.gov · Last updated 23 Mar 2026
Brief summary (registry, in English)
The goal of this study is to learn more about how sotatercept works and if it helps the lung arteries become healthier. Sotatercept will be associated with the following: 1. Improvement in capillary blush, reduce the tapering and tortuosity of affected vessels on pulmonary wedge angiography and decreased wall thickness on intravascular ultrasound in previously affected areas. 2. Improvement in previously poorly or non-perfused areas rather than increased perfusion to previously perfused areas. 3. No changes in baseline ventilation and improvement and ventilation/perfusion matching.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 30 (estimated)
- First submitted
- 2 Mar 2026
- Start date
- 15 Mar 2026
- Primary completion date
- 15 Mar 2028
- Lead sponsor
- Franz Rischard, DO
- NCT number
- NCT07487441
What you commit to
- Study type: Observational
- Planned participants: 30
- From 15 Mar 2026 to the primary completion date, 15 Mar 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior exposure to sotatercept
Other illness
- Contraindication to right heart catheterization (per PI)
Lab values
- Hemoglobin \> 18 g/dL at screening
- Estimated GFR \< 30 mL/min at screening
- Platelet count \<30 at screening
Other
- Positive pregnancy test
Who the study is looking for
- Group 1 Pulmonary Hypertension (G1PH)-must be idiopathic, drug induced, or hereditary (D/H/I)
- Age \< 65 years at time of diagnosis
- Must be 18 years of age or older
- Group 1 Pulmonary Hypertension (G1PH)-all types
- Must be treatment naïve
- Must be 18 years of age or older
- Group 1 Pulmonary Hypertension (G1PH)-all types
- Must be 18 years of age or older
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Clinical and Translational Sciences Research Center Coordinator of this site? Confirm its status | Tucson | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.